Lerado Financial Group Co (HKSE:01225) Research & Development: HK$0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01225 Lerado Financial Group Co Ltd HKSE:01225
33 GF Score
Price HK$0.24
GF Value HK$0.10
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lerado Financial Group Co Research & Development?

Lerado Financial Group Co HKSE:01225 +0.43% 33 Research & Development is HK$0.0 Mil as of Dec. 2025. GuruFocus rates HKSE:01225 with a GF Score™ of 33/100 and a GF Value™ of HK$0.10 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Lerado Financial Group Co's Research & Development for the six months ended in Dec. 2025 was HK$0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.0 Mil.

Lerado Financial Group Co  (HKSE:01225) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lerado Financial Group Co Research & Development Related Terms

Lerado Financial Group Co Research & Development Historical Data

* Premium members only.

The historical data trend for Lerado Financial Group Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lerado Financial Group Co Research & Development Chart

Lerado Financial Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lerado Financial Group Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:01225
33GF Score
Lerado Financial Group Co Ltd HKSE:01225
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lerado Financial Group Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$0.0 Mil mean?
Lerado Financial Group Co (HKSE:01225) has a Research & Development of HK$0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Lerado Financial Group Co and its competitors.
Is Lerado Financial Group Co's Research & Development too high?
Lerado Financial Group Co's current Research & Development is HK$0.0 Mil. Overall, Lerado Financial Group Co has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lerado Financial Group Co's Research & Development compare to MS and GS?
Lerado Financial Group Co's Research & Development of HK$0.0 Mil can be compared against companies in the Capital Markets industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Capital Markets company?
A good Research & Development depends on the Capital Markets industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Lerado Financial Group Co and its competitors. Lerado Financial Group Co's current Research & Development is HK$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lerado Financial Group Co stock overvalued right now?
Based on GuruFocus' analysis, Lerado Financial Group Co (HKSE:01225) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.10, compared to a current price of HK$0.24 — trading 136% above its estimated fair value. The current Research & Development is HK$0.0 Mil. Lerado Financial Group Co's overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Lerado Financial Group Co (HKSE:01225), the current Research & Development is HK$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lerado Financial Group Co (HKSE:01225) Overvalued in 2026?

Based on GuruFocus' analysis, Lerado Financial Group Co stock appears to be overvalued. The current stock price of HK$0.24 is trading 136% above its estimated GF Value™ of HK$0.10. GuruFocus considers Lerado Financial Group Co to be Significantly Overvalued.

Key valuation signals for HKSE:01225:

  • Research & Development: HK$0.0 Mil
  • GF Value™: HK$0.10 vs. price of HK$0.24 (136% above fair value)
  • GF Score™: 33/100 with 5 warning signs

No single metric tells the full story. See the HKSE:01225 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lerado Financial Group Co Business Description

Address 59-67 Bonham Strand West, Flat F&G, 4th Floor., Golden Sun Centre, Sheung Wan, Hong Kong, HKG
Lerado Financial Group Co Ltd is an investment holding company. It is engaged in financial services, including securities broking, margin financing, and money lending, as well as manufacturing and distributing children's plastic toys and medical care products like mobility aids and other medical equipment. The group's operating segments are the Medical products and plastic toys business, Securities brokerage business and asset management services, and Money lending business and other financial services. It derives key revenue from the Medical products and plastic toys business segment, which involves the manufacturing and distribution of medical care products and plastic toys. It has a business presence in Hong Kong, Europe, the U.S., the PRC, Australia, South America, and other countries.
33GF Score

Get the complete analysis for HKSE:01225

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.24
Price
HK$0.10
GF Value